Immutep Limited (IMM:ASX)

19.0¢

right-arrow Created with Sketch. 0.005 (2.7%)
Last trade 16.10pm 12/08/2020 20mins delayed

Company Overview

Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.

IMM in the news

Biotechnology company Immutep (IMM) has been granted a new patent by the…

IMM in the news

Cancer treatment company Immutep (IMM) has released results from two separate clinical…
Biotech company Immutep (IMM) has received €2,173,454 (roughly A$3.6 million) from the…
Biotech company Immutep (IMM) has been granted a patent from the Japanese…
Biotech company Immutep (IMM) has successfully completed a $12 million placementApproximately 96…